Cell Biotech Obtains New European Patent for Kimchi Probiotic 'CBT-SL4' Gastrointestinal Treatment

Confirmation of Probiotic Drug Delivery System Function

[Asia Economy Reporter Lee Gwan-joo] Microbiome specialist company Cell Biotech announced on the 22nd that it has newly acquired a European patent related to the development of gastrointestinal therapeutics for its patented kimchi lactic acid bacteria strain 'CBT-SL4 (Pediococcus Pentosaceus)'.

This patent pertains to gastrointestinal therapeutic drug delivery microorganisms that express and secrete cystatin A, proving that the patented strain CBT-SL4 developed by Cell Biotech functions as a drug delivery vehicle.

Cell Biotech is developing a colon cancer treatment by utilizing this strain to create a lactic acid bacteria drug delivery system (DDS), which continuously expresses the patented anticancer protein 'P8' in the intestines. The lactic acid bacteria drug delivery system is developed as an oral medication, offering high convenience of administration, improving safety and efficiency by reducing side effects and economic burdens of existing treatments. Since it delivers drugs directly to the disease site, higher therapeutic efficacy is expected.

Ryu Yong-gu, Deputy Director of Cell Engineering Research Center at Cell Biotech, stated, “This patent acquisition is significant as it secures technological competitiveness in the global microbiome therapeutics market through overseas patent preemption,” and added, “We plan to expand our research and development pipeline for various gastrointestinal therapeutics using the already secured genetic technology platform.”

This content was produced with the assistance of AI translation services.